Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.55 |
| ▸ | ERN1 | O75460 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | MAX | P61244 | 1/20 | 0.47 |
| ▸ | S100A4 | P26447 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | HNF4A | P41235 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2349847 | 0.85 | ALDH1A1 (0.70) | ERN1TDP1ALDH1A1CASP6MYC | |
| SCHEMBL5605382 | 0.85 | TDP1 (0.69) | GPR35ERN1TDP1ALDH1A1CASP6 | |
| SCHEMBL31415060 | 0.85 | ERN1 (0.59) | GPR35ERN1TDP1ALDH1A1CASP6 | |
| SCHEMBL408308 | 0.85 | ERN1 (0.59) | GPR35ERN1TDP1ALDH1A1CASP6 | |
| SCHEMBL4348393 | 0.81 | ERN1 (0.54) | GPR35ERN1TDP1CASP6TSHR | |
| SCHEMBL2409428 | 0.80 | TPMT (0.49) | TDP1ALDH1A1CASP6MYCMAX | |
| SCHEMBL11309776 | 0.79 | GPR35 (0.78) | GPR35ERN1TDP1ALDH1A1S100A4 | |
| SCHEMBL10598796 | 0.76 | TTR (0.52) | TDP1ALDH1A1TSHRLMNATTR | |
| SCHEMBL9557826 | 0.76 | CASP6 (0.66) | ERN1TDP1CASP6TSHRLMNA | |
| SCHEMBL23499301 | 0.74 | ERN1 (0.57) | ERN1TDP1ALDH1A1CASP6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113929626-A | Method for synthesizing eltrombopag | 苏州特瑞药业有限公司 | 2022-01-14 | — | — | CN | claimed |
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | claimed |
| EP-1294378-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | claimed |
| EP-1294378-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2001089457-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | claimed |
| CN-113929626-A | Method for synthesizing eltrombopag | 苏州特瑞药业有限公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-113929626-A | Method for synthesizing eltrombopag | 苏州特瑞药业有限公司 | 2022-01-14 | — | — | CN | disclosed |
| US-20150093356-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2015-04-02 | — | — | US | disclosed |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2013-03-28 | — | — | US | disclosed |
| US-20110212054-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC. | 2011-09-01 | — | — | US | disclosed |
| US-7790704-B2 | Thrombopoietin mimetics | GlaxoSmithKline, LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7674887-B2 | Thrombopoietin mimetics | GLAXOSMITHKLINE LLC (US) | 2010-03-09 | — | — | US | disclosed |
| US-7335649-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1889838-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2008-02-20 | — | — | EP | disclosed |
| US-7332481-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1864981-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070179192-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED | 2007-08-02 | — | — | US | disclosed |
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-7160870-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | GPR35 2399/4885ERN1 4239/4885TDP1 2922/4885 |
| US-20070179192-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | GPR35 2399/4885ERN1 4239/4885TDP1 2922/4885 |
| US-20150093356-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | GPR35 2399/4885ERN1 4239/4885TDP1 2922/4885 |
| US-20110212054-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | GPR35 2399/4885ERN1 4239/4885TDP1 2922/4885 |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | GPR35 2399/4885ERN1 4239/4885TDP1 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.